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reviewed the current evidence and found no significant 
differences in risk of transplant outcomes: primary non-
function (RR = 0.02, 95%CI: 0.01-0.03, P  = 0.36) and 
one-year post-transplant graft survival (RR = 0.80, 
95%CI: 0.80-0.80, P  = 0.37) between UW and the 
other examined solutions.
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INTRODUCTION
Organ transplantation is inevitably associated with 
ischemia-reperfusion (IR) injury; several methods 
have thus been formulated to reduce IR-related 
morbidity and to maintain the viability of tissues[1,2]. The 
introduction of the University of Wisconsin (UW) solution 
in 1987 has led to significant clinical progress and 
increased cold ischemic tolerance and has become the 
most widely used, gold standard preservation solution 
for liver transplantation[3]. Nevertheless, in spite of the 
clinical success, it has many potential shortcomings 
(Table 1). UW is an intracellular colloid solution with 
high potassium and low sodium concentration that 
inhibits activity of Na-K-adenosine triphosphatase 
and the resultant depletion of adenosine triphosphate 
stores. However, its low sodium content promotes the 
accumulation of calcium during ischemia, resulting in 
calcium-dependent endothelial dysfunction in renal 
glomeruli and in bile ducts during reperfusion[4,5]. 
Additionally, the high potassium increases the risk for 
hyperkalemia-induced cardiac arrest, requiring liver 
flushing before reperfusion. Moreover, low temperature 
storage in the container bag may result in the formation 
of adenosine crystals[6]. Therefore, the use of UW has 
been intensively challenged, and alternative solutions 
with potentially more benefits were developed. Among 
them, histidine-tryptophan-ketoglutarate (HTK), Celsior 
(CS) and Institut George Lopez (IGL-1) are the most 
commonly used preservation solutions in transplantation 
centers[7].
A number of prospective trials have investigated the 
effects of these preservation solutions on liver transplant 
outcomes over many years with variable results. HTK, 
also known as Bretschneider’s solution, is mostly used 
in European liver transplantation centers, especially in 
Germany. It has very low viscosity, which is based on 
a histidine buffer system with two additional substrates 
(tryptophan and ketoglutarate). A lower index of 
viscosity allows faster cooling and, theoretically, an 
Published online: April 28, 2018
Abstract
AIM
To compare the effects of the four most commonly 
used preservation solutions on the outcome of liver 
transplantations.
METHODS
A systematic literature search was performed using 
MEDLINE, Scopus, EMBASE and the Cochrane Library 
databases up to January 31st, 2017. The inclusion 
criteria were comparative, randomized controlled trials 
(RCTs) for deceased donor liver (DDL) allografts with 
adult and pediatric donors using the gold standard 
University of Wisconsin (UW) solution or histidine-
tryptophan-ketoglutarate (HTK), Celsior (CS) and 
Institut Georges Lopez (IGL-1) solutions. Fifteen RCTs 
(1830 livers) were included; the primary outcomes 
were primary non-function (PNF) and one-year post-
transplant graft survival (OGS-1). 
RESULTS
All trials were homogenous with respect to donor 
and recipient characteristics. There was no statistical 
difference in the incidence of PNF with the use of UW, 
HTK, CS and IGL-1 (RR = 0.02, 95%CI: 0.01-0.03, 
P  = 0.356). Comparing OGS-1 also failed to reveal 
any difference between UW, HTK, CS and IGL-1 (RR 
= 0.80, 95%CI: 0.80-0.80, P  = 0.369). Two trials 
demonstrated higher PNF levels for UW in comparison 
with the HTK group, and individual studies described 
higher rates of biliary complications where HTK and CS 
were used compared to the UW and IGL-1 solutions. 
However, the meta-analysis of the data did not prove a 
statistically significant difference: the UW, CS, HTK and 
IGL-1 solutions were associated with nearly equivalent 
outcomes.
CONCLUSION
Alternative solutions for UW yield the same degree of 
safety and effectiveness for the preservation of DDLs, 
but further well-designed clinical trials are warranted.
Key words: Liver transplantation; Preservation solution; 
Primary non-function; One-year post-transplant graft 
survival; Systematic review; Meta-analysis
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: The University of Wisconsin (UW) solution 
is the gold standard for static cold storage in liver 
transplantation. Numerous clinical trials have investi-
gated the potential benefit of the most frequently 
used alternative solutions, histidine-tryptophan-
ketoglutarate, Celsior and Institut Georges Lopez, but 
their results have been variable. This meta-analysis has 
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improved washout of blood cells from the graft[8]. UW 
was first compared to HTK in a randomized fashion 
in liver transplantation in 1994, and these solutions 
were found to have similar outcomes in terms of initial 
non-function of the graft and 30-mo patient survival[9]. 
However, more recent studies with a larger liver 
transplant population from Europe and North America 
have provided different conclusions[10,11].
CS has initially been applied in heart transplantation 
and then for kidney and liver transplantation as well, 
with the idea of providing preservation for all organs 
with a single solution[12]. The use of CS is based on 
similar principles to those of UW and HTK, but certain 
aspects are different. CS and HTK are categorized 
as extracellular preservation fluids; however, their 
buffering systems and substrates, which provide high-
energy phosphates, are different. With its high sodium 
(above 70 mmol/L) and low potassium content, CS is 
specifically designed to limit calcium overload (Table 1). 
It contains reduced glutathione concentration together 
with the addition of mannitol and histidine to prevent 
reactive oxygen species-induced oxidative injury. Like 
HTK, CS is devoid of colloids, therefore resulting in 
decreased viscosity and improved perfusability, it is thus 
unnecessary to the liver prior to reperfusion[13]. Due 
to its characteristically low viscosity, high sodium, low 
potassium and antioxidant properties, CS is considered 
particularly suitable for preserving liver grafts.
There are promising preliminary reports on the 
recently introduced Institut Georges Lopez (IGL-1) 
solution, also known as the UW-polyethylene glycol 
(PEG) solution. IGL-1 combines a cationic inversion 
(lower concentration of potassium) and replacement of 
hydroxyethyl starch with PEG. These properties could 
improve hepatic microcirculatory changes, thereby 
decreasing IR- injury[14]. 
The aim of our study was to provide a systematic 
review of this topic. The goal was to update current 
knowledge and compare data evidence on the 
effectiveness of the most frequently used preservation 
solutions. The primary endpoint of the study was 
primary non-function (PNF) of the graft after liver 
transplantation. PNF is the most common cause of 
early graft loss, and it has been shown that the organ 
preservation method is an independent predictive 
factor of PNF[15]. The secondary endpoint was one-
year post-transplant graft survival (OGS-1), this being 
an appropriate period to evaluate the effect of the 
preservation solutions according to an expert consensus 
opinion[16]. Other outcomes, such as primary dysfunction 
(PDF), early retransplantation rate (RT), post-transplant 
death within 30 d (POD) and one-year post-transplant 
patient survival (OPS-1) were also evaluated together 
with donors and recipient characteristics.
It should be added that three previous systematic 
reviews and two registry data analyses have explored 
this topic, each with limitations[10,16-19]. In 2015, Adam 
et al[10] analyzed the efficacy of the four most commonly 
used preservation solutions based on the European 
Liver Transplant Registry (ELTR) database. The largest 
and most comprehensive study in recent times was 
performed by analyzing outcomes of 42869 (first) 
liver transplantations, including living and deceased 
donors, as well as partial liver graft transplantations. 
Although the study population in this registry data 
analysis was relatively large, non-selective groups of 
donors were included[10,18,20]. Two systematic reviews 
lacked sufficient sample sizes and therefore were 
underpowered to identify clinically relevant differences 
in important outcomes, such as PNF of the graft.[16,17] A 
systematic review by O’Callaghan et al[19] chose 16 RCTs 
for analysis; however, it included unpublished data and 
conference abstracts as well. Since then, new prospective 
trials have also been published, especially with the IGL-1 
solution[8,21]. 
Therefore, the aim of this systematic review was to 
evaluate, compare and update the evidence obtained 
in randomized controlled trials (RCTs) on the efficacy 
of the four most frequently used preservation solutions 
for static cold storage of deceased donor liver (DDL) 
allografts.
MATERIALS AND METHODS
This study was conducted in accordance with the 
PRISMA (Preferred Reporting Items in Systematic 
Reviews and Meta-Analysis) statement[22]. The review 
protocol was registered with the National Institute 
for Health Research PROSPERO system on January 
12th, 2017, and can be found online (Registration No. 
CRD42017054908)[23].
Literature search
A systematic literature search was performed using 
EMBASE/MEDLINE, PubMed, Scopus and Cochrane. 
Database searches were conducted with MeSH key-
words, combined with various terms for organ trans-
plantation and organ preservation solutions (Figure 1). 
No language limitation was applied. The end date for 
the literature search was January 31st, 2017.
Inclusion criteria
Inclusion criteria specified any RCT comparing two or 
more preservation solutions for the static cold storage 
of DDLs, from both adult and pediatric donors. Living 
1814  April 28, 2018|Volume 24|Issue 16|WJG|www.wjgnet.com
UW HTK CS IGL-1 
HES 0.25 - - -
PEG-35 - - - 0.03
Na+   27 15 100 120
K+ 125 10   15   25
Table 1  Ingredients in the investigated preservation solutions
Concentrations are expressed in mmol/L. HES: Hydroxyethyl starch; 
PEG-35: Polyethylene glycol 35 kDa.
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number of patients was used. Any questions in data 
extraction were settled by discussion with a third author.
Statistical analysis
The statistical analysis for this study was conducted 
by Péter Mátrai, Institute of Bioanalysis, University of 
Pécs, H-7624 Pécs, Hungary. Risk ratios (RR) from 
individual studies were pooled statistically by random 
effect model using the DerSimonian-Laird estimator 
and were displayed on forest plots. As RR allows for 
the comparison of two samples, the Celsior and HTK 
solutions were compared to UW. Summary RRs were 
calculated with 95% confidence intervals (CI) and p 
values to test if summary RR = 1 can be rejected. P < 
0.05 was defined as a significant difference between 
solutions. In the analysis of outcomes for PNF and PDF, 
we used a computational correction recommended in 
the Cochrane Handbook and proposed by Sweeting 
et al[24]. to overcome the difficulty of dividing by 0. 
Statistical heterogeneity was tested using the I2 statistic 
and the chi-square test to obtain probability-values; P < 
0.05 was defined to indicate significant heterogeneity. 
All statistical calculations were performed using Stata 
11 SE (Stata Corp) and Comprehensive Meta-analysis 
Software (Version 3, Biostat, Englewood). We sought 
signs of a small study effect with the funnel plot. To 
identify potential sources of heterogeneity, we defined 
a priori subgroup analyses with the model of end-stage 
donor transplantation, multiple organ transplantation, 
retransplantation, nonhuman and uncontrolled studies 
were excluded. Abstracts for inclusion were independently 
reviewed by two authors, and disagreements were 
resolved by discussion with a third author (Figure 1).
Outcomes
The primary outcome was PNF of the liver grafts. PNF 
is a life-threatening condition after transplantation that 
leads to death or to the need for retransplantation within 
seven days of transplantation. It is characterized by 
hepatic cytolysis, elevated fasting transaminase levels, 
diminishing or absent bile production, coalgulation 
deficit related to severely impaired liver function, 
high lactate levels, hypoglycemia, respiratory failure 
requiring ventilatory support, circulatory failure requiring 
catecholamines, and the onset of renal and multi-organ 
failure[15].
The secondary outcome was OGS-1, since the one-
year post-transplant time point was considered by an 
expert consensus opinion as most suitable to evaluate 
the effect of the preservation solutions[16]. 
Data extraction
Demographic, quality and outcome data were extracted 
independently into Microsoft Excel by two authors. Data 
were collected from all articles describing the studies; 
in the case of discrepancies, the article with the largest 
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Organ transplantation AND Organ preservation solution
8944 Abstracts retrieved
2813 EMBASE/MEDLINE, 1426 PubMed, 4588 Scopus, 117 Cochrane
1445 articles after limitation
Human, controlled study
21 articles screened
Human, controlled study
15 full-text articles
assessed for eligibility
15 studies included in
qualitative synthesis
15 studies included in
quantitative synthesis
(meta-analysis)
1348 articles excluded
76 duplicates removed
6 full-text articles
excluded
Figure 1  PRISMA flowchart of search strategy with inclusions and exclusions.
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liver disease (MELD) score and cold ischemia time (CIT). 
All other outcomes related to the solutions were also 
investigated by subgroup analysis. 
RESULTS
Demographic and clinical characteristics of donors and 
recipients were homogenous in all trials (Supplementary 
Tables 1-3).
MELD score
The MELD score incorporates parameters of recipients 
(such as abnormal coagulation, creatinine and serum 
bilirubin levels and the etiology of cirrhosis) and serves 
as a predictor of mortality after liver transplantation[25]. 
MELD scores were reported in five studies (Supple-
mentary Table 2). Subgroup analysis showed no 
significant difference in MELD score between the four 
solutions (RR = 18.6, 95%CI: 15.7-21.5, P = 0.379) 
(Supplementary Figure 1A).
CIT
CIT (time interval from the clamping of the donor 
aorta to the anastomosis of the organ to the recipient’s 
vascular system or organs disposal) was reported in five 
studies (Supplementary Table 3). Subgroup analysis 
showed no significant difference in risk of CIT between 
the four solutions (RR = 484.7, 95%CI: 445.4-524.0, 
P = 0.1) (Supplementary Figure 1B).
PNF
PNF rates were reported in 15 studies (Table 2)[8,9,12,13,21,26-35]. 
In four studies, PNF was defined as patient death or 
retransplantation in the first week. In eleven studies, 
PNF was undefined. Overall rates of PNF were very 
low (range 0-13.7%). Our meta-analysis showed no 
significant difference in risk of PNF between the UW and 
CS solutions (z = 0.41, P = 0.680) and between UW and 
HTK (z = 1.07, P = 0.284) (Figure 2A). We found only 
one RCT that dealt with IGL-1, which was not sufficient 
for a meta-analysis to compare IGL-1 with the UW 
Study Solution 1 Solution 2 RR P value
N n % N n %
Cavallari et al[13], 2003 UW   90 1   1.100 CS   83 0   0.000 2.77 0.53
Lopez-Andujar et al[26], 2009 UW 104 2   1.900 CS   92 2   2.200 0.88 0.90
García-Gil et al[33], 2006 UW   40 0   0.000 CS   40 0   0.000 1.00 1.00
Nardo et al[27], 2001 UW   60 2   3.333 CS   53 0   0.000 4.43 0.33
Duca et al[28], 2010 UW   51 0   0.000 CS   51 0   0.000 1.00 1.00
García-Gil et al[35], 2011 UW   51 4 11.100 CS   51 4 11.100 1.00 1.00
Lama et al[29], 2002 UW   10 0   0.000 CS   10 0   0.000 1.00 1.00
Rayya et al[30], 2008 UW   68 1   1.471 HTK   69 1   1.449 1.01 0.99
Meine et al[32], 2006 UW   65 2   3.070 HTK   37 1   3.030 1.14 0.91
Erhard et al[9], 1994 UW   30 2   6.660 HTK   30 0   0.000 5.00 0.29
Mangus et al[31], 2008 UW   98 5   5.102 HTK 111 3   2.703 1.89 0.38
Dondéro et al[37], 2010 UW   92 4   4.350 IGL-1   48 1   2.080 2.09 0.51
Meine et al[8], 2015 HTK   65 2   3.100 IGL-1 113 3   2.700 1.16 0.87
Wiederkehr et al[21], 2014 HTK 125 1   0.700 IGL-1   53 0   0.000 1.29 0.88
Nardo et al[12], 2005 HTK   20 1   5.000 CS   20 0   0.000 3.00 0.49
Table 2  Primary non-function rate in included studies
Studies are grouped by preservation solutions. PNF: Primary non-function; N: Indicates number in group; n: Number of PNF; RR: Relative risk; UW: 
University of Wisconsin solution; HTK: Histidine-tryptophan-ketoglutarate solution; CS: Celsior solution; IGL-1: Institut Georges Lopez solution.
Study Solution 1 Solution 2 RR P value
N n % N n %
Cavallari et al[13], 2003 UW   90 75 83.0 CS   83 71 85.0 0.97 0.69
Lopez-Andujar et al[26], 2009 UW 104 83 80.0 CS   92 75 81.0 0.98 0.76
García-Gil et al[33], 2006 UW   40 26 66.1 CS   40 31 78.0 0.84 0.22
Nardo et al[27], 2001 UW   60 54 90.0 CS   53 48 90.6 0.99 0.92
Duca et al[28], 2010 UW   51 31 60.6 CS   51 37 73.5 0.84 0.21
Rayya et al[30], 2008 UW   68 53 78.0 HTK   69 49 71.0 1.01 0.35
Meine et al[32], 2006 UW   65 61 94.0 HTK   37 35 94.0 0.99 0.88
Mangus et al[31], 2008 UW   98 82 84.0 HTK 111 95 86.0 0.98 0.70
Dondéro et al[37], 2010 UW   92 73 79.1 IGL-1   48 19 39.8 2.00 0.00
Meine et al[8], 2015 HTK   65 54 83.0 IGL-1 113 96 85.0 0.98 0.74
Nardo et al[12], 2005 HTK   20 15 75.0 CS   20 18 90.0 0.83 0.22
Table 3  One-year post-transplant graft survival rate in included studies
Studies are grouped by preservation solutions. OGS-1: One-year post-transplant graft survival; N: Number in group; n: Number of OGS-1; RR: Relative 
risk; UW: University of Wisconsin solution; HTK: Histidine-tryptophan-ketoglutarate solution; CS: Celsior solution; IGL-1: Institut Georges Lopez solution.
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Study RR (95%CI) Events, 
UW
Events,Comparison 
solution
% 
Weight
Celsior
Lopez-Andujar R. 2009 0.88 (0.13, 6.15)  2/104 2/92   21.45
Duca W. J. 2010   1.00 (0.02, 49.45)  0.5/52 0.5/52     5.30 
García-Gil F. A. 2006   1.00 (0.02, 49.20)  0.5/41 0.5/41     5.32
Lama 2002   1.00 (0.02, 46.05)  0.5/11 0.5/11     5.50 
García-Gil F. A. 2011 1.00 (0.26, 3.78)   4/51  4/51   45.60 
Cavallari A. 2003   2.77 (0.11, 67.05) 1.5/91 0.5/84    7.95
Nardo B. 2001   4.43 (0.22, 90.17) 2.5/61 0.5/54     8.88
Subtotal (I -squared = 0.0%, P  = 0.977) 1.21 (0.49, 2.96) 11.5/411 8.5/385 100.00 
HTK
Rayya F. 2008   1.01 (0.06, 15.90)   1/68  1/69   14.23
Meine M. H. 20064 obse   1.14 (0.11, 12.13)   2/65  1/37   19.24
Mangus 2008 1.89 (0.46, 7.70)   5/98   3/111   54.53
Erhard 1994   5.00 (0.25, 99.95)   2/30  0/30   12.00 
Subtotal (I -squared = 0.0%, P  = 0.857) 1.76 (0.62, 4.98)   10/261    5/247 100.00 
IGL-1
Dondéro F. 2010 2.09 (0.24, 18.16) 4/92 1/48 100.00 
Subtotal (I -squared = .%, P  = .) 2.09 (0.24, 18.16) 4/92 1/48 100.00 
NOTE: Weights are from random effects analysis
0.01                                       1                                       100
Comparison solution UW
A
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B
Study ES (95%CI) % Weight
Celsior
Cavallari A., 2003 0.01 (0.00, 0.09)    4.86
Nardo B., 2001 0.01 (0.00, 0.13)    2.18
Duca W. J., 2010 0.01 (0.00, 0.14)    2.04
García-Gil F. A., 2006 0.01 (0.00, 0.17)     1.35
Lopez-Andujar R., 2009 0.02 (0.01, 0.08)    6.22
Nardo B., 2005 0.02 (0.00, 0.29)    0.46
Lama, 2002 0.05 (0.00, 0.45)    0.19
García-Gil F. A., 2011 0.11 (0.05, 0.23)     1.14
Subtotal (I -squared = 0.0%, P  = 0.711)  0.02 (-0.00, 0.04)   18.45
HTK
Wiederkehr J.C., 2014 0.01 (0.00, 0.05)   12.96
Rayya F., 2008 0.01 (0.00, 0.10)    4.26
Erhard, 1994 0.02 (0.00, 0.21)     0.84
Mangus, 2008 0.03 (0.01, 0.08)    7.27
Meine M. H., 2006 0.03 (0.00, 0.17)     1.37
Meine M. H., 2015 0.03 (0.01, 0.12)     3.25
Nardo B., 2005 0.05 (0.01, 0.28)     0.49
Subtotal (I -squared = 0.0%, P  = 0.964)  0.02 (-0.00, 0.03)   30.44
IGL-1
Wiederkehr J. C., 2014 0.01 (0.00, 0.13)    2.18
Dondéro F., 2010 0.02 (0.00, 0.13)    2.19
Meine M. H., 2015 0.03 (0.01, 0.08)    7.45
Subtotal (I -squared = 0.0%, P  = 0.894)  0.02 (-0.01, 0.05)   11.82
UW
Duca W. J., 2010 0.01 (0.00, 0.14)    2.04
Cavallari A., 2003 0.01 (0.00, 0.07)    7.00
García-Gil F. A., 2006 0.01 (0.00, 0.17)     1.35
Rayya F., 2008 0.01 (0.00, 0.10)    4.14
Lopez-Andujar R., 2009 0.02 (0.00, 0.07)    7.94
Meine M. H., 2006 0.03 (0.01, 0.11)    3.26
Nardo B., 2001 0.03 (0.01, 0.12)    2.81
Dondéro F., 2010 0.04 (0.01, 0.11)    4.49
Lama, 2002 0.05 (0.00, 0.45)    0.19
Mangus, 2008 0.05 (0.02, 0.12)    4.11
Erhard, 1994 0.07 (0.02, 0.23)    0.82
García-Gil F. A., 2011 0.11 (0.05, 0.23)     1.14
Subtotal (I -squared = 0.0%, P  = 0.816) 0.03 (0.01, 0.04)   39.29
Overall (I -squared = 0.0%, P  = 0.992) 0.02 (0.01, 0.03) 100.00 
NOTE: Weights are from random effects analysis
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solution. We performed a subgroup analysis to compare 
the four solutions in the context of PNF. There was no 
significant difference between solutions (RR = 0.02, 
95%CI: 0.01-0.03, P = 0.356) (Figure 2B). We found 
no evidence of a small study effect using the funnel plot 
analysis of the meta-analyses for the primary outcome (P 
= 0.846) (Figure 2C).
OGS-1
OGS-1 was reported in eleven studies (Table 3). No 
study was individually powered for small differences 
in graft survival, and no study reported a difference 
related to the preservation fluid used. Meta-analysis of 
the data showed no significant difference in the risk of 
OGS-1 between the UW and CS solutions (z = 0.30, 
P = 0.763) (Figure 3A) or between the UW and HTK 
solutions (z = 0.01, P = 0.991) (Figure 3A). We also 
performed a subgroup analysis to compare all four 
solutions, including IGL-1. There was no significant 
difference between the solutions (RR = 0.80, 95%CI: 
0.80-0.80, P = 0.369) (Figure 3B). We found no 
evidence of a small study effect using the funnel plot 
analysis from either of the meta-analyses for the 
OGS-1 (P = 0.397) (Figure 3C).
PDF
PDF rates were reported in six studies: five of them 
compared UW with CS, and one compared UW with 
HTK (Supplementary Table 4). Overall rates of PDF 
were very low (range 0-15.5%). The difference in PDF 
rate was found higher with the use of UW solutions in 
one study[32]. However, the subgroup analysis showed 
no increased risk of PDF in the UW group (RR = 0.1, 
95%CI: 0.0-0.1, P = 0.582) (Supplementary Figure 2).
Early RT
Early RT was reported in seven studies and ranged 
from 0.9% to 20% (Supplementary Table 4). None of 
the studies found a significant difference in early RT 
between groups; however, they were underpowered 
to detect such a low incidence outcome. Similarly, 
subgroup analysis showed no increased risk of early 
RT in the UW group (RR = 0.0, 95%CI: 0.0-0.1, P = 
0.698) (Supplementary Figure 3). 
POD
POD rates were reported in seven studies (Supplementary 
Table 4). Overall rates of POD were very low (range 
1.7%-14.4%). The difference in POD rate was higher 
with the use of the CS solution compared with the UW 
solution in two studies[12,33]; however, subgroup analysis 
showed no increased risk (Supplementary Figure 4). In 
contrast, there was a significant difference when UW 
was compared to HTK or IGL-1 (RR = 0.07, 95%CI: 
0.04-0.09, P < 0.01). 
OPS-1
OPS-1 rates were reported in ten studies (Supplementary 
Table 4). No study was individually powered for small 
differences in graft survival, and no study reported 
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Figure 2  Effects of preservation solutions on primary non-function. A: Meta-analysis of the relative risk (-RR-) of PNF comparing studies using different 
preservation solutions: UW vs Celsior and UW vs HTK; B: Forest plot for subgroup analysis of PNF; and C: Funnel plot for PNF in studies. Squares represent 
individual study effects, with the size of the box relating to the weight of the study in the meta-analysis. Each diamond represents a summary effect from meta-
analysis. Horizontal bars represent 95% CIs. There is no evidence of a small study effect in the test or the formal plot. PNF: Primary non-function; RCTs: Randomized 
controlled trials; ES: Effect size; UW: University of Wisconsin solution; HTK: Histidine-tryptophan-ketoglutarate solution; CS: Celsior solution; IGL-1: Institut Georges 
Lopez solution.
Begg's funnel plot with pseudo 95% confidence limits
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Study RR (95%CI) Events, 
UW
Events,Comparison 
solution
% Weight
Celsior
Duca W. J. 2010 0.84 (0.63, 1.11) 31/51 37/51    6.24
García-Gil F. A. 2006 0.84 (0.63, 1.11) 26/40 31/40    6.04
Cavallari A. 2003 0.97 (0.86, 1.11) 75/90 71/83   29.39
Lopez-Andujar R. 2009 0.98 (0.85, 1.12)   83/104 75/92   25.56
Nardo B. 2001 0.99 (0.88, 1.12) 54/60 48/53   32.78
Subtotal (I -squared = 0.0%, P  = 0.639) 0.96 (0.90, 1.03) 269/345 262/319 100.00 
HTK
Mangus 2008 0.98 (0.87, 1.10) 82/98   95/111   36.73
Meine M. H. 20063 obse 0.99 (0.90, 1.10) 61/65 35/37   50.48
Rayya F. 2008 1.10 (0.90, 1.34) 53/68 49/69   12.79
Subtotal (I -squared = 0.0%, P  = 0.557) 1.00 (0.93, 1.07) 196/231 179/217 100.00 
IGL-1
Dondéro F. 2010 2.00 (1.39, 2.89) 73/92 19/48 100.00 
Subtotal (I -squared = .%, P  = .) 2.00 (1.39, 2.89) 73/92 19/48 100.00 
NOTE: Weights are from random effects analysis
0.3                                    1                                  3
Comparison solution UW
A
Study ES (95%CI) % Weight
Celsior
Duca W. J., 2010 0.7 (0.6, 0.8)     4.06
García-Gil F. A., 2006 0.8 (0.6, 0.9)     3.87
Lopez-Andujar R., 2009 0.8 (0.7, 0.9)     5.01
Cavallari A., 2003 0.9 (0.8, 0.9)     5.07
Nardo B., 2005 0.9 (0.7, 1.0)     3.41
Nardo B., 2001 0.9 (0.8, 1.0)     4.93
Subtotal (I -squared = 32.3%, P  = 0.194) 0.8 (0.8, 0.9)   26.36
HTK
Rayya F., 2008 0.7 (0.6, 0.8)     4.39
Nardo B., 2005 0.8 (0.5, 0.9)     2.74
Meine M. H., 2015 0.8 (0.7, 0.9)     4.73
Mangus, 2008 0.9 (0.8, 0.9)     5.36
Meine M. H., 2006 0.9 (0.8, 1.0)     4.75
Subtotal (I -squared = 65.8%, P  = 0.020) 0.8 (0.8, 0.9)    21.97
IGL-1
Dondéro F., 2010 0.4 (0.3, 0.5)     3.71
Meine M. H., 2015 0.9 (0.8, 0.9)     5.34
Subtotal (I -squared = 97.1%, P  = 0.000) 0.6 (0.2, 1.1)     9.05
UW
Duca W. J., 2010 0.6 (0.5, 0.7)     3.80
García-Gil F. A., 2006 0.7 (0.5, 0.8)     3.54
Rayya F., 2008 0.8 (0.7, 0.9)     4.58
Dondéro F., 2010 0.8 (0.7, 0.9)     4.95
Lopez-Andujar R., 2009 0.8 (0.7, 0.9)     5.09
Cavallari A., 2003 0.8 (0.7, 0.9)     5.07
Mangus, 2008 0.8 (0.8, 0.9)     5.18
Nardo B., 2001 0.9 (0.8, 1.0)     5.03
Meine M. H., 2006 0.9 (0.8, 1.0)     5.39
Subtotal (I -squared = 76.0%, P  = 0.000) 0.8 (0.7, 0.9)   42.62
Overall (I -squared = 77.3%, P  = 0.000) 0.8 (0.8, 0.8) 100.00 
NOTE: Weights are from random effects analysis
0   0.2 0.4 0.6 0.8   1
B
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a difference related to the preservation fluid used. 
Subgroup analysis showed no significant difference in risk 
of OPS-1 between the four solutions (RR = 0.9, 95%CI: 
0.8-0.9, P = 0.786) (Supplementary Figure 5).
DISCUSSION
This study reviews the current evidence and updates 
knowledge on four frequently used preservation solutions 
for static cold storage of DDLs for transplantation. The 
treatment groups were homogenous in terms of donor 
and recipient characteristics; the prediction of primary 
and secondary outcomes (i.e., PNF and OGS-1) was thus 
likely independent of individual risk variables, patient 
selection or the overall severity of the disease at liver 
transplantation. More importantly, the analysis of 
outcome parameters (i.e., PNF and OGS-1) provided 
good evidence that UW is not outperformed by CS, 
HTK and IGL-1 solutions in maintaining organ function 
and viability of liver grafts in cold storage. 
PNF mainly depends on the organ preservation 
method[15]. It occurs in 2%-6% of transplants and is 
unrelated to any direct surgical, immunologic or other 
complications[34]. Our meta-analysis included eleven 
trials that evaluated the effectiveness of the UW 
solution as compared to either the CS or HTK solution. 
In accordance with the literature, the overall rates 
of PNF were very low, except in one trial (13%)[35]. 
When analyzing the single studies, we found two 
trials with a higher incidence of PNF in the UW group 
than in the HTK group[9,36], but the difference did not 
reach statistical significance upon meta-analysis. It 
should be added that a recent analysis of the ELTR 
database demonstrated that use of HTK represented an 
individual risk factor for the development of PNF when 
compared to the UW solution[10]. The contradictory 
conclusions can be explained with the selection bias of 
the database analysis[20]. In either case, we found no 
difference between UW and the other solutions with 
regard to the risk of PNF. As regards IGL-1 and HTK, 
two prospective randomized clinical studies with 356 
patients reported identical results[8,21]. Similar outcome 
was detected in a single-center study with 140 patients 
that compared IGL-1 and UW solutions[37]. This was 
confirmed in the current study, since IGL-1 showed a 
similar PNF risk to that of UW and HTK in our subgroup 
analyses. 
In our study, OGS-1 was the secondary endpoint. 
Graft survival rates were evaluated one, three and five 
years after liver transplantation in single studies. The 
one-year term was chosen as an appropriate period 
to evaluate the effect of the preservation solutions 
because other factors could have a greater impact on 
this outcome parameter after this time. A retrospective 
analysis of the ELTR database demonstrated that HTK 
preservation was independently associated with higher 
mortality than UW, CS and IGL-1 in a multivariate 
analysis[10]. Another analysis of a large national registry 
database (United Network for Organ Sharing, UNOS) 
has also demonstrated differences in graft survival 
rate between the HTK and UW solutions[18]. However, 
important risk factors among donors were not con-
sidered in the ELTR analysis[20], and selected groups 
of transplant patients were not homogenous in the 
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Figure 3  Effects of preservation solutions on one-year post-transplant graft survival. A: Meta-analysis of the relative risk (-RR-) of OGS-1 comparing studies 
using different preservation solutions: UW vs Celsior and UW vs HTK; B: Forest plot for subgroup analysis of OGS-1; and C: Funnel plot for OGS-1 in studies. 
Squares represent individual study effects, with the size of the box relating to the weight of the study in the meta-analysis. Each diamond represents a summary effect 
from meta-analysis. Horizontal bars represent 95% CIs. There is no evidence of a small study effect in the test or the formal plot. OGS-1: One-year post-transplant 
graft survival; RR: Relative risk; RCTs: Randomized controlled trials; ES: Effect size; UW: University of Wisconsin solution; HTK: Histidine-tryptophan-ketoglutarate 
solution; CS: Celsior solution; IGL-1: Institut Georges Lopez solution.
Begg's funnel plot with pseudo 95% confidence limits
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other analysis: HTK was utilized in allografts with more 
favorable recipient traits, as well as shorter CIT and 
less local and national export[18]. In accordance with 
the findings from numerous clinical trials, the meta-
analyses and subgroup analyses in this study did not 
show a significant difference in risk of OGS-1 between 
UW and any of the examined solutions. Similarly, there 
was no evidence for a difference between IGL-1 and UW 
solutions and between IGL-1 and HTK in the subgroup 
analyses. 
Apart from the preservation methods used to protect 
the organ from IR injury, the final outcome of trans-
plantation can also be linked to factors such as donor 
age, general condition and CIT[38]. A recent UNOS study 
showed a more pronounced risk for graft loss with 
longer CIT and donors over 70 years[18]. In our study, 
subgroup analysis showed that the included trials did 
not vary significantly and that the mean CITs were 
beyond the critical 12 h[39]. Several experimental studies 
demonstrated that the use of the UW solution allows for 
longer CITs with better graft preservation; however, it 
remains to be determined whether any of the alternative 
solutions is better than UW when CIT is prolonged over 
12 h. 
Recipient morbidity and MELD scores are also 
important contributing factors to the outcome of liver 
transplantation. Recipient parameters are incorporated 
into the MELD score, which indicates the state of 
health of the recipient; the MELD score-based organ 
allocation algorithm could thus significantly influence 
the graft survival rate[40]. In the present study, there 
was no significant difference between the preservation 
solutions in the context of the MELD score and other 
recipient characteristics.
In recent times, the crisis in organ supply has made 
it necessary to extend the scope of potential donors 
by using extended criteria donors (ECD). Although 
there is no precise definition of ECD, frequently cited 
characteristics are donor age, steatosis, donation 
after cardiac death (DCD), donors with increased 
risk of disease transmission and transplantation after 
prolonged CIT, as well as the use of partial grafts 
(split grafts and living donor liver transplantation)[41]. 
Unfortunately, higher rates of graft failure were 
documented in this class of extended allograft; in 
addition, very little data is available on the influence 
of preservation solutions on their post-transplant 
outcomes[42]. A single-center study by Mangus et al[30] 
failed to find statistically significant differences in over-
all graft survival when they compared UW to HTK in 
ECD transplantations. However, they suggested that 
HTK may be protective against biliary complications. 
In contrast, in 2009, the UNOS database analysis 
reported that HTK was associated with an increased 
risk of graft loss and early graft loss[18]. More recently, 
Adam et al[10] compared the four most frequently used 
preservation solutions and concluded that HTK is an 
independent risk factor for graft loss after ECD liver 
transplantations. The remaining three solutions, UW, CE 
and IGL-1, provided similar results in post-transplant 
outcomes after ECD transplantations. In the special 
condition of using a partially deceased donor liver graft, 
IGL-1 offered the best graft outcome[10]. In another 
study, it was suggested that IGL-1 was superior to 
other solutions for preserving fatty livers by protecting 
against PNF and early allograft dysfunction[43]. However, 
a prospective randomized study could not show any 
significant improvement in the subgroup of patients 
receiving IGL-1-preserved grafts[36]. In living donor 
liver transplantations, risk-adjusted analyses of single- 
and double-center studies consistently reported that 
UW and HTK were equally effective and safe for cold 
preservation[44-47]. There is currently no evidence-based 
recommendation on the optimal preservation solution 
in ECD liver transplantations because the number and 
quality of RCTs are not sufficient. However, based on 
the above data, differences in the indications of various 
preservation solutions are expected.
This study has some limitations. There are so far 
only three small RCTs that compare IGL-1 with UW or 
IGL-1 with HTK. Therefore, we could not run a meta-
analysis to compare IGL-1 with any of the solutions. In 
order to compare the risk of the four solutions for PNF, 
we had to perform a subgroup analysis. In addition, 
surgery time and hemoderivative transfusions due to 
recipient coagulation problems are often not cited in the 
literature as predictors of poor outcome[36]. This factor 
was not considered in the selected trials. Moreover, 
different trials presented some differences as regards 
the operative procedure. Furthermore, the included 
RCTs were homogenous with regard to donor and 
recipient parameters. On the one hand, this provided 
the possibility to exclude selection bias, but, on the 
other hand, the effects of preservation solutions in the 
case of longer CIT and involvement of expanded criteria 
donors could not be evaluated. 
In conclusion, elucidation of the role of preservation 
solutions in the outcome of liver transplantation is 
complicated by the intrinsic complexity of the clinical 
procedure, which is made up of many different, but 
interacting phases. This review evaluated the best 
available evidence from comparisons of the four most 
frequently used preservation fluids in DDL transplan-
tation. A direct meta-analysis comparison was made 
and the sample size of included trials was large enough 
to estimate the risk of low-incidence outcomes such as 
PNF or OGS-1 correctly. Based on our results, there is 
good evidence that the UW, CS, HTK and IGL-1 solutions 
are associated with nearly equivalent outcomes. 
Additional studies on larger patient populations including 
marginal donors, longer cold ischemia time, multi-organ 
transplantations and economic aspects are needed to 
evaluate the superiority of any alternative solution over 
UW. 
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ARTICLE HIGHLIGHTS
Research background
The introduction of the University of Wisconsin (UW) solution for static cold 
storage of liver grafts was a breakthrough and has remained the conventional 
method of organ preservation. However, many alternative preservation 
solutions exist, and each is thought to offer an advantage over UW solution.
Research motivation
At present, 98% of liver transplantations use the UW, histidine-tryptophan-
ketoglutarate (HTK), Celsior (CS) or Institute Georges Lopez (IGL-1) solution for 
the cold preservation of grafts. Previously, prospective trials have investigated 
their effects on liver transplant outcomes, but with contradictory results. 
Furthermore, no systematic review reports the effect of IGL-1, which was first 
used by 2003, as compared to other solutions.
Research objectives
To provide an update and to compare the latest findings from clinical trials 
on the effects of the four most frequently used preservation solutions on liver 
transplant outcomes.
Research methods
A systematic review and meta-analysis were conducted on randomized 
controlled trials of deceased donor liver transplantations using UW and either 
HTK, CS or IGL-1 for cold storage of allografts. Primary and secondary 
outcomes were primary non-function (PNF) and one-year post-transplant graft 
survival (OGS-1).
Research results
In spite of differences found in individual studies, a meta-analysis of PNF and 
OGS-1 showed no statistical difference between groups. Subgroup analysis 
showed no increased risk for other outcomes, such as primary dysfunction, 
early retransplantation rate, post-transplantation death and one-year post-
transplant patient survival.
Research conclusions
This meta-analysis provided evidence that UW and alternative solutions 
are associated with almost the same transplant outcome. Further studies 
are needed with extended criteria donors to ascertain the superiority of any 
alternative solution over UW.
REFERENCES
1 Jia JJ, Li JH, Jiang L, Lin BY, Wang L, Su R, Zhou L, Zheng SS. 
Liver protection strategies in liver transplantation. Hepatobiliary 
Pancreat Dis Int 2015; 14: 34-42 [PMID: 25655288 DOI: 10.1016/
S1499-3872(15)60332-0]
2 Brisson H, Arbelot C, Monsel A, Parisot C, Girard M, Savier E, 
Vezinet C, Lu Q, Vaillant JC, Golmard JL, Gorochov G, Langeron 
O, Rouby JJ; Members of the Pitié-Salpêtrière Liver Transplantation 
Study Group. Impact of graft preservation solutions for liver 
transplantation on early cytokine release and postoperative organ 
dysfunctions. A pilot study. Clin Res Hepatol Gastroenterol 2017; 41: 
564-574 [PMID: 28330599 DOI: 10.1016/j.clinre.2016.12.011]
3 Stewart ZA. UW solution: still the “gold standard” for liver 
transplantation. Am J Transplant 2015; 15: 295-296 [PMID: 
25612481 DOI: 10.1111/ajt.13062]
4 Sanchez-Urdazpal L, Gores GJ, Ward EM, Maus TP, Wahlstrom 
HE, Moore SB, Wiesner RH, Krom RA. Ischemic-type biliary 
complications after orthotopic liver transplantation. Hepatology 
1992; 16: 49-53 [PMID: 1618482 DOI: 10.1002/hep.1840160110]
5 Cutrin JC, Cantino D, Biasi F, Chiarpotto E, Salizzoni M, 
Andorno E, Massano G, Lanfranco G, Rizzetto M, Boveris A, Poli 
G. Reperfusion damage to the bile canaliculi in transplanted human 
liver. Hepatology 1996; 24: 1053-1057 [PMID: 8903374 DOI: 
10.1002/hep.510240512]
6 Tullius SG, Filatenkow A, Horch D, Mehlitz T, Reutzel-Selke 
A, Pratschke J, Steinmüller T, Lun A, Al-Abadi H, Neuhaus P. 
Accumulation of crystal deposits in abdominal organs following 
perfusion with defrosted University of Wisconsin solutions. Am 
J Transplant 2002; 2: 627-630 [PMID: 12201363 DOI: 10.1034/
j.1600-6143.2002.20707.x]
7 Fridell JA, Rogers J, Stratta RJ. The pancreas allograft donor: 
current status, controversies, and challenges for the future. Clin 
Transplant 2010; 24: 433-449 [PMID: 20384731 DOI: 10.1111/
j.1399-0012.2010.01253.x]
8 Meine MH, Leipnitz I, Zanotelli ML, Schlindwein ES, Kiss G, 
Martini J, de Medeiros Fleck A Jr, Mucenic M, de Mello Brandão 
A, Marroni CA, Craco Cantisani GP. Comparison Between 
IGL-1 and HTK Preservation Solutions in Deceased Donor Liver 
Transplantation. Transplant Proc 2015; 47: 888-893 [PMID: 
26036479 DOI: 10.1016/j.transproceed.2015.03.033]
9 Erhard J, Lange R, Scherer R, Kox WJ, Bretschneider HJ, 
Gebhard MM, Eigler FW. Comparison of histidine-tryptophan-
ketoglutarate (HTK) solution versus University of Wisconsin (UW) 
solution for organ preservation in human liver transplantation. 
A prospective, randomized study. Transpl Int 1994; 7: 177-181 
[PMID: 8060466]
10 Adam R, Delvart V, Karam V, Ducerf C, Navarro F, Letoublon 
C, Belghiti J, Pezet D, Castaing D, Le Treut YP, Gugenheim 
J, Bachellier P, Pirenne J, Muiesan P; ELTR contributing 
centres, the European Liver, Intestine Transplant Association 
(ELITA). Compared efficacy of preservation solutions in liver 
transplantation: a long-term graft outcome study from the European 
Liver Transplant Registry. Am J Transplant 2015; 15: 395-406 
[PMID: 25612492 DOI: 10.1111/ajt.13060]
11 Fridell JA, Agarwal A, Milgrom ML, Goggins WC, Murdock P, 
Pescovitz MD. Comparison of histidine-tryptophan-ketoglutarate 
solution and University of Wisconsin solution for organ 
preservation in clinical pancreas transplantation. Transplantation 
2004; 77: 1304-1306 [PMID: 15114104 DOI: 10.1097/01.
TP.0000122222.93740.B2]
12 Nardo B, Bertelli R, Montalti R, Beltempo P, Puviani L, Pacilè 
V, Cavallari A. Preliminary results of a clinical randomized study 
comparing Celsior and HTK solutions in liver preservation for 
transplantation. Transplant Proc 2005; 37: 320-322 [PMID: 
15808630 DOI: 10.1016/j.transproceed.2004.11.028]
13 Cavallari A, Cillo U, Nardo B, Filipponi F, Gringeri E, Montalti 
R, Vistoli F, D’amico F, Faenza A, Mosca F, Vitale A, D’amico 
D. A multicenter pilot prospective study comparing Celsior and 
University of Wisconsin preserving solutions for use in liver 
transplantation. Liver Transpl 2003; 9: 814-821 [PMID: 12884193 
DOI: 10.1053/jlts.2003.50161]
14 Tabka D, Bejaoui M, Javellaud J, Roselló-Catafau J, Achard JM, 
Abdennebi HB. Effects of Institut Georges Lopez-1 and Celsior 
preservation solutions on liver graft injury. World J Gastroenterol 
2015; 21: 4159-4168 [PMID: 25892865 DOI: 10.3748/wjg.v21.
i14.4159]
15 Ploeg RJ, D’Alessandro AM, Knechtle SJ, Stegall MD, Pirsch JD, 
Hoffmann RM, Sasaki T, Sollinger HW, Belzer FO, Kalayoglu M. 
Risk factors for primary dysfunction after liver transplantation--a 
multivariate analysis. Transplantation 1993; 55: 807-813 [PMID: 
8475556]
16 Lema Zuluaga GL, Serna Agudelo RE, Zuleta Tobón JJ. 
Preservation solutions for liver transplantation in adults: celsior 
versus custodiol: a systematic review and meta-analysis with an 
indirect comparison of randomized trials. Transplant Proc 2013; 45: 
25-32 [PMID: 23267794 DOI: 10.1016/j.transproceed.2012.02.031]
17 Feng L, Zhao N, Yao X, Sun X, Du L, Diao X, Li S, Li Y. 
Histidine-tryptophan-ketoglutarate solution vs. University of 
Wisconsin solution for liver transplantation: a systematic review. 
Liver Transpl 2007; 13: 1125-1136 [PMID: 17665493 DOI: 
10.1002/lt.21208]
18 Stewart ZA, Cameron AM, Singer AL, Montgomery RA, Segev 
Szilágyi ÁL et al . Meta-analysis of liver graft preservation solutions
 ARTICLE HIGHLIGHTS
1823  April 28, 2018|Volume 24|Issue 16|WJG|www.wjgnet.com
DL. Histidine-Tryptophan-Ketoglutarate (HTK) is associated with 
reduced graft survival in deceased donor livers, especially those 
donated after cardiac death. Am J Transplant 2009; 9: 286-293 
[PMID: 19067658 DOI: 10.1111/j.1600-6143.2008.02478.x]
19 O’Callaghan JM, Morgan RD, Knight SR, Morris PJ. The 
effect of preservation solutions for storage of liver allografts 
on transplant outcomes: a systematic review and meta-
analysis. Ann Surg 2014; 260: 46-55 [PMID: 24374537 DOI: 
10.1097/SLA.0000000000000402]
20 Nashan B, Spetzler V, Schemmer P, Kirste G, Rahmel A. 
Regarding “Compared Efficacy of Preservation Solutions in Liver 
Transplantation: A Long-Term Graft Outcome Study From the 
European Liver Transplant Registry”. Am J Transplant 2015; 15: 
3272-3273 [PMID: 26555321 DOI: 10.1111/ajt.13513]
21 Wiederkehr JC, Igreja MR, Nogara MS, Goncalves N, Montemezzo 
GP, Wiederkehr HA, Wassen MP, Nobrega HA, Zenatti KB, Mori 
LY, Tudisco MS. Use of IGL-1 preservation solution in liver 
transplantation. Transplant Proc 2014; 46: 1809-1811 [PMID: 
25131043 DOI: 10.1016/j.transproceed.2014.05.040]
22 Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. 
Preferred reporting items for systematic reviews and meta-
analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097 
[PMID: 19621072 DOI: 10.1371/journal.pmed.1000097]
23 The University of York Centre for Reviews and Dissemination. 
PROSPERO Register of ongoing systematic reviews. Available 
from: https://www.crd.york.ac.uk/PROSPERO/display_record.
asp?ID=CRD42017054908
24 Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? 
Use and avoidance of continuity corrections in meta-analysis of 
sparse data. Stat Med 2004; 23: 1351-1375 [PMID: 15116347 DOI: 
10.1002/sim.1761]
25 Huo TI, Lee SD, Lin HC. Selecting an optimal prognostic system 
for liver cirrhosis: the model for end-stage liver disease and 
beyond. Liver Int 2008; 28: 606-613 [PMID: 18433390 DOI: 
10.1111/j.1478-3231.2008.01727.x]
26 Lopez-Andujar R, Deusa S, Montalvá E, San Juan F, Moya A, 
Pareja E, DeJuan M, Berenguer M, Prieto M, Mir J. Comparative 
prospective study of two liver graft preservation solutions: 
University of Wisconsin and Celsior. Liver Transpl 2009; 15: 
1709-1717 [PMID: 19938119 DOI: 10.1002/lt.21945]
27 Nardo B, Catena F, Cavallari G, Montalti R, Di Naro A, Faenza A, 
Cavallari A. Randomized clinical study comparing UW and Celsior 
solution in liver preservation for transplantation: preliminary 
results. Transplant Proc 2001; 33: 870-872 [PMID: 11267110 
DOI: 10.1016/S0041-1345(00)02357-5]
28 Duca WJ, da Silva RF, Arroyo PC Jr, Sgnolf A, Cabral CM, Ayres 
DC, Felício HC, da Silva RD. Liver transplantation using University 
of Wisconsin or Celsior preserving solutions in the portal vein 
and Euro-Collins in the aorta. Transplant Proc 2010; 42: 429-434 
[PMID: 20304157 DOI: 10.1016/j.transproceed.2010.01.035]
29 Lama C, Rafecas A, Figueras J, Torras J, Ramos E, Fabregat J, 
Busquets J, Garcia-Barrasa A, Jaurrieta E. Comparative study 
of Celsior and Belzer solutions for hepatic graft preservation: 
preliminary results. Transplant Proc 2002; 34: 54-55 [PMID: 
11959183 DOI: 10.1016/S0041-1345(01)02664-1]
30 Rayya F, Harms J, Martin AP, Bartels M, Hauss J, Fangmann J. 
Comparison of histidine-tryptophan-ketoglutarate solution and 
University of Wisconsin solution in adult liver transplantation. 
Transplant Proc 2008; 40: 891-894 [PMID: 18555073 DOI: 
10.1016/j.transproceed.2008.03.044]
31 Mangus RS, Fridell JA, Vianna RM, Milgrom MA, Chestovich 
P, Chihara RK, Tector AJ. Comparison of histidine-tryptophan-
ketoglutarate solution and University of Wisconsin solution in 
extended criteria liver donors. Liver Transpl 2008; 14: 365-373 
[PMID: 18306380 DOI: 10.1002/lt.21372]
32 Meine MH, Zanotelli ML, Neumann J, Kiss G, de Jesus Grezzana 
T, Leipnitz I, Schlindwein ES, Fleck A Jr, Gleisner AL, de Mello 
Brandão A, Marroni CA, Cantisani GP. Randomized clinical assay 
for hepatic grafts preservation with University of Wisconsin or 
histidine-tryptophan-ketoglutarate solutions in liver transplantation. 
Transplant Proc 2006; 38: 1872-1875 [PMID: 16908310 DOI: 
10.1016/j.transproceed.2006.06.071]
33 García-Gil FA, Arenas J, Güemes A, Esteban E, Tomé-Zelaya 
E, Lamata F, Sousa R, Jiménez A, Barrao ME, Serrano MT. 
Preservation of the liver graft with Celsior solution. Transplant 
Proc 2006; 38: 2385-2388 [PMID: 17097942 DOI: 10.1016/j.trans
proceed.2006.08.032]
34 Uemura T, Randall HB, Sanchez EQ, Ikegami T, Narasimhan G, 
McKenna GJ, Chinnakotla S, Levy MF, Goldstein RM, Klintmalm 
GB. Liver retransplantation for primary nonfunction: analysis of a 
20-year single-center experience. Liver Transpl 2007; 13: 227-233 
[PMID: 17256780 DOI: 10.1002/lt.20992]
35 García-Gil FA, Serrano MT, Fuentes-Broto L, Arenas J, García 
JJ, Güemes A, Bernal V, Campillo A, Sostres C, Araiz JJ, Royo 
P, Simón MA. Celsior versus University of Wisconsin preserving 
solutions for liver transplantation: postreperfusion syndrome and 
outcome of a 5-year prospective randomized controlled study. 
World J Surg 2011; 35: 1598-1607 [PMID: 21487851 DOI: 
10.1007/s00268-011-1078-7]
36 Mangus RS, Kinsella SB, Nobari MM, Fridell JA, Vianna RM, 
Ward ES, Nobari R, Tector AJ. Predictors of blood product use in 
orthotopic liver transplantation using the piggyback hepatectomy 
technique. Transplant Proc 2007; 39: 3207-3213 [PMID: 
18089355 DOI: 10.1016/j.transproceed.2007.09.029]
37 Dondéro F, Paugam-Burtz C, Danjou F, Stocco J, Durand F, 
Belghiti J. A randomized study comparing IGL-1 to the University 
of Wisconsin preservation solution in liver transplantation. Ann 
Transplant 2010; 15: 7-14 [PMID: 21183870]
38 Stahl JE , Kreke JE, Malek FA, Schaefer AJ, Vacanti J. 
Consequences of cold-ischemia time on primary nonfunction and 
patient and graft survival in liver transplantation: a meta-analysis. 
PLoS One 2008; 3: e2468 [PMID: 18575623 DOI: 10.1371/
journal.pone.0002468]
39 Belle SH ,  Beringer KC, Detre KM. An update on liver 
transplantation in the United States: recipient characteristics and 
outcome. Clin Transpl 1995; 19-33 [PMID: 8794252]
40 Weismüller TJ, Fikatas P, Schmidt J, Barreiros AP, Otto G, 
Beckebaum S, Paul A, Scherer MN, Schmidt HH, Schlitt HJ, 
Neuhaus P, Klempnauer J, Pratschke J, Manns MP, Strassburg CP. 
Multicentric evaluation of model for end-stage liver disease-based 
allocation and survival after liver transplantation in Germany-
-limitations of the ‘sickest first’-concept. Transpl Int 2011; 24: 
91-99 [PMID: 20819196 DOI: 10.1111/j.1432-2277.2010.01161.x]
41 Vodkin I, Kuo A. Extended Criteria Donors in Liver Transplantation. 
Clin Liver Dis 2017; 21: 289-301 [PMID: 28364814 DOI: 10.1016/
j.cld.2016.12.004]
42 Nemes B, Gámán G, Polak WG, Gelley F, Hara T, Ono S, 
Baimakhanov Z, Piros L, Eguchi S. Extended-criteria donors in liver 
transplantation Part II: reviewing the impact of extended-criteria 
donors on the complications and outcomes of liver transplantation. 
Expert Rev Gastroenterol Hepatol 2016; 10: 841-859 [PMID: 
26831547 DOI: 10.1586/17474124.2016.1149062]
43 Zaoualí MA, Mosbah IB, Abdennebi HB, Calvo M, Boncompagni 
E, Boillot O, Peralta C, Roselló-Catafau J. New insights into fatty 
liver preservation using Institute Georges Lopez preservation 
solution. Transplant Proc 2010; 42: 159-161 [PMID: 20172305 
DOI: 10.1016/j.transproceed.2009.12.035]
44 Kaltenborn A, Gwiasda J, Amelung V, Krauth C, Lehner F, Braun 
F, Klempnauer J, Reichert B, Schrem H. Comparable outcome 
of liver transplantation with histidine-tryptophan-ketoglutarate 
vs. University of Wisconsin preservation solution: a retrospective 
observational double-center trial. BMC Gastroenterol 2014; 14: 
169 [PMID: 25263587 DOI: 10.1186/1471-230X-14-169]
45 Moray G, Sevmis S, Karakayali FY, Gorur SK, Haberal M. 
Comparison of histidine-tryptophan-ketoglutarate and University 
of Wisconsin in living-donor liver transplantation. Transplant Proc 
2006; 38: 3572-3575 [PMID: 17175334 DOI: 10.1016/j.transproce
Szilágyi ÁL et al . Meta-analysis of liver graft preservation solutions
1824  April 28, 2018|Volume 24|Issue 16|WJG|www.wjgnet.com
ed.2006.10.174]
46 Jain A, Mohanka R, Orloff M, Abt P, Kashyap R, Cullen J, 
Lansing K, Bozorgzadeh A. University of Wisconsin versus 
histidine-tryptophan-ketoglutarate for tissue preservation in live-
donor liver transplantation. Exp Clin Transplant 2006; 4: 451-457 
[PMID: 16827642]
47 Ringe B, Braun F, Moritz M, Zeldin G, Soriano H, Meyers W. 
Safety and efficacy of living donor liver preservation with HTK 
solution. Transplant Proc 2005; 37: 316-319 [PMID: 15808629 
DOI: 10.1016/j.transproceed.2004.12.009]
P- Reviewer: Bramhall S, Chiu KW, Inoue K, Rosello-Catafau J, Tsoulfas G 
S- Editor: Gong ZM    L- Editor: A    E- Editor: Huang Y
Szilágyi ÁL et al . Meta-analysis of liver graft preservation solutions
                                      © 2018 Baishideng Publishing Group Inc. All rights reserved.
Published by Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.f6publishing.com/helpdesk
http://www.wjgnet.com
I S S N  1 0  0 7  -   9  3 2  7
9    7 7 1 0  07   9 3 2 0 45
1  6
